Laura Airas
Research
Publications
2024
P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study
Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki E, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, Airas L. P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study. EJNMMI Research 2024, 14: 123. PMID: 39636350, PMCID: PMC11621262, DOI: 10.1186/s13550-024-01186-3.Peer-Reviewed Original ResearchPerilesional rimTracer bindingDisability progressionMS patientsMS brainsLesion rimWhite matterProgressive MS patientsPro-inflammatory microgliaRelapsed patientsSmoldering inflammationT1 lesionsMales compared to femalesNew-onsetProgressive patientsTracer uptakeParent tracerP2XDisease durationProgressive MSHealthy controlsPatientsPET studiesPerilesional areaFree fraction156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataSmouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions
Scalfari A, Traboulsee A, Oh J, Airas L, Bittner S, Calabrese M, Dominguez J, Granziera C, Greenberg B, Hellwig K, Illes Z, Lycke J, Popescu V, Bagnato F, Giovannoni G. Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions. Annals Of Neurology 2024, 96: 826-845. PMID: 39051525, DOI: 10.1002/ana.27034.Peer-Reviewed Original ResearchMultiple sclerosisProgression independent of relapse activityCognitive symptomsIndependent of relapse activitySuppression of relapseInternational consensus statementClinical implicationsRelapse activityTherapeutic suppressionClinical trialsConsensus statementFuture directionsTherapeutic targetRoutine practicePathological substrateProgressive independencePathological processesSafety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Doerner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Wiendl H, Maurer M, Gimenez-Arnau A, Chitnis T. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204912.Peer-Reviewed Original ResearchSex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals
Laaksonen S, Saraste M, Nylund M, Hinz R, Snellman A, Rinne J, Matilainen M, Airas L. Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals. Frontiers In Neurology 2024, 15: 1352116. PMID: 38445263, PMCID: PMC10913932, DOI: 10.3389/fneur.2024.1352116.Peer-Reviewed Original ResearchDistribution volume ratioNormal-appearing white matterMale MS patientsCortical gray matterMS patientsPositron emission tomographyTSPO bindingMultiple sclerosisDisease progressionHealthy individualsClinical disease progressionWhole-brainBrain positron emission tomographySex differencesMales compared to femalesFemale patientsHealthy womenDisability progressionGreater likelihoodGray matterHealthy controlsStudy cohortFemale controlsEmission tomographyBrainA review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Airas L, Bermel R, Chitnis T, Hartung H, Nakahara J, Stuve O, Williams M, Kieseier B, Wiendl H. A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis. Therapeutic Advances In Neurological Disorders 2024, 17: 17562864241233041. PMID: 38638671, PMCID: PMC11025433, DOI: 10.1177/17562864241233041.Peer-Reviewed Original ResearchBruton tyrosine kinase inhibitorChronic spontaneous urticariaFirst-generation BTK inhibitorSystemic lupus erythematosusBruton's tyrosine kinaseTyrosine kinase inhibitorsMS disease-modifying treatmentsBTK inhibitorsDisease-modifying treatmentsSafety profileB cellsMultiple sclerosisChronic useRheumatoid arthritisSecond-generation BTK inhibitorsB cell depletion therapyTreatment of B-cell malignanciesB-cell modulationDiverse autoimmune conditionsPhase II trialGadolinium-enhancing lesionsB-cell malignanciesMagnetic resonance imaging scansLong-term administrationFemale reproductive health
2023
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
Oh J, Airas L, Harrison D, Järvinen E, Livingston T, Lanker S, Malik R, Okuda D, Villoslada P, de Vries H. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. Frontiers In Neurology 2023, 14: 1319869. PMID: 38107636, PMCID: PMC10722910, DOI: 10.3389/fneur.2023.1319869.Peer-Reviewed Original ResearchMultiple sclerosisClinical trialsMonitoring of MSMagnetic resonance imagingPositron emission tomographyDisability worseningKey unmetCentral pathologyEarly pathologyTreatment responseNew therapiesOcular imagingUnmet needResonance imagingEmission tomographyDisease pathologyNew therapeuticsPathologyNeuroimaging measuresTrialsLongitudinal studySclerosisClinicWorseningBiomarkersPhase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis
Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, Loop B, Hayek G, Bhatt A, Hunter B, Zhang Y, Karan R, Willi R, Kieseier B, Montalban X. Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2023, 80: 105315. DOI: 10.1016/j.msard.2023.105315.Peer-Reviewed Original ResearchBruton's tyrosine kinaseDisease activitySerum neurofilament light chain concentrationNeurofilament light chain concentrationOpen-label extensionKey secondary endpointDisability Status ScaleNew oral treatmentRecent disease activityLight chain concentrationsPercentage of participantsCovalent BTK inhibitorImmune regulatory networkRelated neuroinflammationDisability progressionPrimary endpointSecondary endpointsT1 lesionsTyrosine kinaseOral treatmentRelapse rateT2 lesionsMulticenter studyMultiple sclerosisSafety profileRemibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015)
Williams M, Airas L, Chitnis T, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, Ziehn M, Willi R, Kieseier B, Nikolaev I, Haemmerle S, Zharkov A, Siegel R, Cenni B, Wiendl H, Maurer M, Giménez-Arnau A, Montalban X. Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202933.Peer-Reviewed Original ResearchInternational Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013)
Bagnato F, Scalfari A, Oh J, Airas L, Bittner S, Calabrese M, Dominguez J, Granziera C, Greenberg B, Hellwig K, Illes Z, Lycke J, Traboulsee A, Popescu V, Giovannoni G. International Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203661.Peer-Reviewed Original Research
Get In Touch
Contacts
Email